GREY MICHAEL G 4

What Happened

• Michael G. Grey, a director of Mirum Pharmaceuticals (MIRM), was granted equity awards on 2026-06-15 consisting of two awards: 3,772 derivative shares and 1,980 restricted stock units (RSUs). Both grants were recorded at $0.00 per share (no cash paid). Total awarded shares: 5,752. This is a grant/award (compensation), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (appears timely under the 2-business-day rule).
• Grants: 3,772 derivative shares (A) and 1,980 RSUs (A); acquisition price $0.00 for each.
• Total shares awarded: 5,752.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnotes:
  • F1: The derivative shares vest on the first anniversary of the grant date; will be fully vested by the issuer's 2027 annual stockholder meeting.
  • F2: Each RSU equals a contingent right to one common share and vests on the first anniversary of the grant date; will be fully vested by the 2027 annual stockholder meeting.
• No indication this was part of a 10b5-1 plan, tax withholding, or an immediate sale.

Context

• RSUs and derivative awards are standard director compensation designed to align interests with shareholders; they are not the same as a cash purchase and do not by themselves signal buying or selling sentiment.
• Vesting conditions mean Grey must remain a director (or meet any other vesting conditions) until vesting; the awards convert to actual shares only when vested.